ANTI-LAG-3 BINDENDE PROTEINE

European patent · EP2970464 · In force

Register entry

Publication number
EP2970464
Application number
EP14709691
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 13, 2014
Published
Jan 20, 2016
Granted
May 6, 2020
Protection ends at the latest
Mar 12, 2034
Next annual fee due
Mar 31, 2027
IPC classes
C07K 16/28 (2006.01)
A61P 37/04 (2006.01)
Priority
US 201361789325 P 15.03.2013
PCT application
PCT/EP2014/054967 13.03.2014
PCT publication
WO2014/140180 18.09.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  2. Nov 7, 2025

    Holder’s address changed

    Owner
    GlaxoSmithKline Intellectual Property Development, Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom → GlaxoSmithKline Intellectual Property Development, Limited, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom

    Published in Swissreg on 07.11.2025

  3. Apr 1, 2025

    Change

    Published in Swissreg on 01.04.2025

  4. Apr 1, 2024

    Change

    Published in Swissreg on 01.04.2024

  5. Apr 1, 2023

    Change

    Published in Swissreg on 01.04.2023

  6. Jul 15, 2020

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich

    Published in Swissreg on 15.07.2020

  7. May 6, 2020

    Granted

    Published in Swissreg on 06.05.2020

Parties

Inventor

HAMBLIN, Paul Andrew

Stevenage Hertfordshire SG1 2NY, GB

LEWIS, Alan Peter

Stevenage Hertfordshire SG1 2NY, GB

WEBB, Thomas Matthew

Brentford Middlesex TW8 9GS, GB

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.